changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
London, UK, 09 September 2016
LONDON, UK: BTG plc (LSE: BTG), an international specialist healthcare company, today announced the launch of the βETA™ Radiation Safety Programme, a new initiative designed to reduce the risk of radiation exposure when performing selective internal radiation therapy (SIRT) with Y90 microspheres. Developed in collaboration with global experts, including Professor Jacob Kamen of the Mount Sinai Medical Center, the βETA™ Radiation Safety Programme analyses current practise and exposure risk, and provides recommendations to improve safety for healthcare professionals and patients.
The βETA™ Radiation Safety Programme, launching at the 2016 CIRSE (Cardiovascular and Interventional Radiological Society of Europe) International Conference in Barcelona, Spain is a new online resource featuring a range of educational tools and materials on radiation protection, health and safety. Uniquely, the resource provides users with proprietary audit tools to assess the risk of radiation exposure associated with selective internal radiation therapy (SIRT) with Y90 microspheres. It offers advice and guidance on reducing exposure levels for healthcare professionals and patients pre, during and post procedure. In addition, the βETA™ Radiation Safety Programme includes a collaborative feedback tool for users to add best practice experience, ensuring the resource is continually updated and expert knowledge is shared.
“With the rapid pace of development of new radiation treatments, there is a real need for education on best practice which is current to treatments being used today, such as SIRT,” said Professor Jacob Kamen, Chief Radiation and Laser Safety Officer, Associate Professor of Radiology at Mount Sinai Medical Center, New York, US. “This need for continual education requires a resource that is easy to access at any time, from anywhere, and is updated regularly. The development of the βETA™ Radiation Safety Programme is informed by expert views from many of the leading global experts on radiation risk, and has been designed to ensure that this expert knowledge can be applied directly to current clinical practice.”
Information regarding the βETA™ Radiation Safety Programme is available via the BTG booth at CIRSE 2016. Healthcare professionals can access the programme at www.btg-beta.com.
About BTG Interventional Medicine
BTG Interventional Medicine is part of BTG plc, a growing international specialist healthcare company. As medicine moves from major surgery to minor procedure, from the systemic to the local, no company endeavors to do more than BTG Interventional Medicine to help doctors in their quest to see more, reach further and treat smarter. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots, and varicose veins. To learn more about BTG Interventional Medicine, please visit: btg-im.com.
For further information contact:
Chris Sampson, Corporate Communications Director
+44 20 7575 1595; Mobile: +44 7773 251 178
+44 208 618 2755; Mobile: +44 7725 925 841
Select CONTINUE to proceed to the BTG website or LEAVE to learn more at BSC.com